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were previously characterized using a home-made PCR assay performed on Rotor-
GeneTM 6000 (Corbett Research) with the following settings: 200μl of whole blood 
extracted with QIAamp® DNA blood (Qiagen), reaction mixture (fi nal volume of 
20 μl) consisting of 1 μl of genomic DNA, 8 μl of Thermo Absolute Blue QPCR mix 
(Thermo Scientifi c), primers and probes (fi nal concentration): 
• F2for, 5’-CCGCTGGTATCAAATGGG-3’ (0.8 μM); 
•  F2rev, 5’-CCAGTAGTATTACTGGCTCTTCCTG-3’ (10 μM); 
• F2S, 5’-CTCAGCAAGCCTCAATG-3’-FL (10 μM); 
•  F2A, 5’-LCred670-TCCCAGTGCTATTCATGGGC-3’-PHO (10 μM); 
• F5for, 5’-CCCCATTATTTAGCCAGGAG-3’ (10 μM); 
• F5rev, 5’-ATGAGAGACATCGCCTCTGG-3’ (0.8 μM); 
•  F5S, 5’-AGATCCCTGGACAGGCAAGGAATA-3’-FL (10 μM); 
•  F5A, 5’-LCred670-GGTATTTTGTCCTTGAAGTAACCTTTCAG-3’-PHO 
(10 μM).
PCR programs are described below (table 1)
Results: 46 Xpert® FII and FV results totally agreed with the home-made PCR: 
1 homozygous mutant, 14 heterozygous and 33 homozygous wild-type for FII and 6 
homozygous mutant, 20 heterozygous and 22 homozygous wild-type for FV.
However, 2 out of the 42 whole blood samples (4.8%) were tagged as INVALID 
by GeneXpert®, even after retest. These results are probably due to PCR inhibition.
Conclusion: The GeneXpert® FII and FV results were concordant with our 
reference technique. However, the proportion of INVALID samples should not be 
overlooked. This fully automated system is fast, easy to use and doesn’t require any 
particular infrastructure.
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Introduction: The G1691A factor V (FV) (Leiden) and G20210A factor II (FII) 
mutations are the most common genetic predispositions to deep venous thrombosis. In this 
study, the Xpert® FII and FV assay performed on GeneXpert® system (Cepheid) has been 
evaluated. This system performs a fully-automated real-time PCR in less than one hour.
Materials and Methods: The analytical performance of GeneXpert® FII and 
FV assay was determined using a panel of 42 stored (-20°C) EDTA anti-coagulated 
whole blood samples as well as 6 DNA quality controls (RFB, Boon). The samples 
Table 1 – Abstract 349 – Rotor-Gene PCR cycling program and melting curve analysis
Cycles FII Temperature, °C FII Time, s FV Temperature, °C FV Time, s
1 95 900 95 900
50x 95
55
72
15
30
15
95
54
72
10
20
15
1 95 15 94 15
1 40 90 40 60
1 50 150
Melting curve Temperature, °C Ramp rate, °C/s Temperature, °C Ramp rate, °C/s
40 to 70 1°C/4s 50 to 85 1°C/4s
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After ischemic stroke, clinicians are faced with problems of tissue reperfusion 
and reocclusion, in which platelet activation/aggregation could play a key role. 
Our laboratory has shown that PJ34, a potent poly(ADP-ribose) polymerase 
(PARP) inhibitor, is neuroprotective and reduces hemorrhagic transformations 
after cerebral ischemia. Besides, some studies suggest that certain PARP inhibitors 
could have an antiplatelet effect*. In this context, we evaluated the effect of PJ34 
on platelet functions.
Platelet-rich plasma, obtained from citrated blood of donors, was preincubated with 
PJ34 (1–100 μM). ADP-, collagen- or PAR1.ap-induced aggregation was quantifi ed 
by optical aggregometry. ADP was used at concentration (1.5-5 μM) producing a 
biphasic aggregation curve resulting from the activation of the two ADP receptors 
P2Y1 and P2Y12, respectively.
To confi rm the effect of PJ34 on P2Y12, we measured VASP-P (vasodilator-
stimulated phosphoprotein phosphorylated), a marker of P2Y12 inhibition. Citrated 
blood was preincubated with PJ34 (100-1000 μM) and the assay was conducted with 
the PLT VASP/P2Y12 fl ow cytometry kit. Results were expressed as Platelet Reactivity 
Index (PRI); a low PRI is associated with a high VASP-P and a low P2Y12 functionality.
PJ34 inhibited the 2nd phase of ADP-induced platelet aggregation (P2Y12-dependent) 
by 60% at 10 μM (p<0.01) and totally at 100 μM (p<0.001) without any effect on the 
1st aggregation phase. The more ADP concentrations increased, the less PJ34 had an 
inhibitory effect. Collagen- and PAR1.ap-induced platelet aggregation were not modifi ed.
PJ34 reduced the PRI in a dose-dependent manner by 30% at 250 μM (p<0.01) 
and totally at 1000 μM (p<0.001).
These results suggest that PJ34 exerts in vitro an inhibitory effect on ADP-induced 
platelet aggregation via a competitive P2Y12 antagonism. This antiplatelet effect 
strengthens the interest of PJ34 in the treatment of cerebral ischemia.
*Alexy et al.2004.J Cardiovasc Pharmacol,43:423
